Biogen Ends Collaboration with Sage Therapeutics on SAGE-324
Biogen and Sage Therapeutics Collaboration Concludes
In a notable shift within the biotech arena, Sage Therapeutics Inc has disclosed that Biogen Inc has officially ended its collaboration and licensing agreement concerning the SAGE-324 program. This decision arrives in the wake of recent Phase 2 KINETIC 2 study results that were disappointing for the chronic treatment of essential tremor (ET).
Negative Results from KINETIC 2 Study
The collaborative KINETIC 2 study aimed to evaluate the dose-response relationship of SAGE-324 for ET, a neurological disorder characterized by involuntary trembling in various body parts. Sadly, the study results did not meet expectations, indicating no statistically significant dose-response relationship, particularly concerning the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 total score.
Understanding Essential Tremor
Essential tremor can dramatically affect individuals' daily lives, making simple tasks such as writing or holding objects difficult. The implications of such a disorder can be far-reaching, influencing both mental and emotional health. The recent study's failure signals a need for continued exploration of alternative treatment pathways for those impacted by the condition.
Impact on SAGE-324 Development
In light of the setbacks, Sage Therapeutics and Biogen will discontinue the ongoing open-label safety study for the investigational drug SAGE-324 in ET, with no plans for future clinical development in this area. From the date of termination, set for February 17, 2025, Sage will regain full ownership of the SAGE-324 asset and evaluate other potential indications where the compound may be beneficial.
Future Considerations for Sage Therapeutics
Despite the cessation of SAGE-324 development for essential tremor, Sage Therapeutics remains proactive in exploring additional treatment avenues. Their commitment to advancing psychiatric and neurological healthcare is unwavering, and innovative solutions are still within reach.
Continued Partnership on Zurzuvae
Interestingly, amidst this collaboration termination, Biogen and Sage Therapeutics will continue to work together on Zurzuvae (zuranolone), recognized as the first FDA-approved oral treatment aimed at addressing postpartum depression. This collaboration represents a significant effort in enhancing mental health solutions, highlighting the companies' dedication to tackling pressing healthcare needs.
Market Reaction and Stock Performance
On the market front, the recent developments have seen a positive trend in stock prices. As per the latest updates, SAGE stock rose by 1.42%, trading at $7.12, while BIIB stock saw an increase of 1.77% to $192.42. This market optimism suggests investor confidence despite the challenges faced by the companies.
Frequently Asked Questions
What prompted the end of the collaboration between Biogen and Sage Therapeutics?
The collaboration was terminated due to disappointing results from the Phase 2 KINETIC 2 study for SAGE-324, which did not show a statistically significant effect for treating essential tremor.
What is SAGE-324, and what condition was it being developed for?
SAGE-324 is an investigational treatment that was being evaluated for its effectiveness in treating essential tremor, a neurological condition characterized by involuntary shaking.
Will Sage Therapeutics continue to develop SAGE-324?
While development for SAGE-324 in essential tremor will cease, Sage Therapeutics plans to explore other potential indications for the compound.
What other products do Biogen and Sage Therapeutics collaborate on?
The two companies will continue their collaboration on Zurzuvae (zuranolone), an FDA-approved oral treatment for postpartum depression.
How did the stock market react to this news?
Following the announcement, SAGE stock increased by 1.42%, trading at $7.12, while BIIB stock rose 1.77%, reaching $192.42, suggesting a positive response from investors.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- World of Dypians Achieves Milestone Recognition by Binance
- Municipality Finance Launches EUR 50 Million Note Offer
- Nexstim Expands Its Footprint in Finland with New Order
- Van Leeuwen Pipe and Tube Group Receives Royal Honor for 100 Years
- September Brings Relief as French Inflation Slows Down
- Exploring Kamala Harris' Vision for a Fairer Economy
- VINCI Secures Major Highway Concession Amid Infrastructure Growth
- SES Plans Substantial Shareholder Returns with New Dividend
- Shigeru Ishiba's Vision for a Resilient Japan Ahead
- Japan Stock Market Sees Gains with Nikkei 225 Up Over 2%
Recent Articles
- U.S. Auto Sales Insights: Trends and Future Predictions
- Techint Labs Launches Innovative Website for Future Growth
- Medical Gas and Equipment Market Expected to Surge by 2029
- Innovative Sock Matcher Designed to Simplify Laundry Tasks
- Building Sustainable Food Practices Through Collaboration
- Top Carbon Market Investment Insights: Colombian Success
- AIIB Welcomes Nauru as Its 110th Member for Global Growth
- Randstad US Achieves Leadership Recognition in 2024 Industry Assessment
- Airbus Faces Delivery Challenges Affecting Annual Goals
- iQIYI Launches 300+ Shows, Boosts Short Drama Production
- First Solar Gains Favor with Analysts Due to Strong Positioning
- Validus Energy's Strategic Acquisition of Citizen Energy Expands Growth
- Understanding the Fed's Emergency Policy on Discount Window Use
- U.S. Home Sales Show Signs of Life Amid Rate Cuts
- New Initiative by Fed's Williams to Enhance Rate Benchmarking
- August Sees Unexpected Increase in US Capital Goods Orders
- Economic Challenges in Argentina: An Austerity Perspective
- How Austerity Measures Affect Argentina's Poverty Levels
- Huddle01 Unveils Upcoming Sale to Revolutionize Video Communication
- Palantir Technologies: Future Prospects and Current Triumphs
- Underground Cable Accessories Market to Surpass $35 Billion
- SCORE Marks Six Decades of Empowering Small Businesses Across USA
- Safety Shot Spinoff Offers Shareholders a New Dividend Opportunity
- Investors Urged to Act After Methode Electronics Lawsuit News
- Leveraging Opportunities: PenFed Foundation Supports Veterans
- Exploring Growth in the Medical Device Contract Manufacturing Sector
- Enhancing Cannabis Entrepreneurship: CannaCon Midwest in Cleveland
- Carson Wealth Strengthens Billings Presence with True North
- Ohio Liquor's Award Highlights Commitment to Innovation
- COP28 President Urges Global Leaders to Pursue Ambitious NDCs
- Westinghouse Bolsters Canadian Nuclear Supply Chain with MoUs
- Celebrating Excellence: 2024 Healthcare Leadership Awards
- Urteste Advances on New Cancer Diagnostic Innovations
- Understanding Homeowner Insurance Trends: New Insights for 2024
- Investors' Insights on L3Harris Technologies Inc. Metrics
- HaystackID Enhances AI Offerings with Relativity Integration
- Unlocking Nebraska's Cannabis Market: Insights from an Expert
- Understanding Treasury Bond ETFs and Inflation's Impact
- Innovative Product Offers Dual Benefits for Smokers and Users
- NSSF's Insightful Report Card Highlights Congressional Actions
- Leadership Transitions at Jenner & Block: A New Era Begins
- Cleanroom Technologies Projected to Reach $12.3 Billion by 2029
- Revolutionizing Biopharma with AbZelectPRO™: A New Era in Cell Line Development
- Excitement Builds for the 2025 Westminster Dog Show Event
- Innovative Strategic Partnership to Transform Advisor Engagement
- Babson Diagnostics Collaborates with Orchard for BetterWay Testing
- Gracenote and Amagi Revolutionize Streaming with New Partnership
- Pending Home Sales Reflect Strength Amid Market Challenges
- InflaRx's Gohibic Trial Insights Propel Confidence Amid Challenges
- Performance Food Group Co Hits New Heights in Stock Market